Baxter Reports Third-Quarter 2026 Results, Delivering Growth Across All Business Segments
Baxter International, a global medical technology company, has announced its financial results for the third quarter of 2026, reporting growth in worldwide sales across its business segments and continued progress in strengthening its financial position. The company recorded approximately $2.98 billion in worldwide sales for the quarter, representing a 5% increase on both a reported and organic basis, while continuing to focus on operational improvements, balance sheet stability and long-term growth.
The latest results reflect performance across Baxter’s Medical Products & Therapies and Healthcare Systems & Technologies segments. The company reported increased sales in the United States and international markets, supported by demand for infusion therapies, intravenous solutions, advanced surgery products, surgical systems and patient support technologies.
Baxter also reported $448 million in free cash flow for the third quarter, bringing its year-to-date free cash flow to $705 million. In addition, the company completed a $600 million cash tender offer during the quarter, retiring $864 million of debt as part of its efforts to accelerate deleveraging and support its investment-grade credit objectives.
Andrew Hider, president and chief executive officer of Baxter, said the company delivered a strong quarter, with growth across its business segments and divisions globally. He noted that Baxter continues to make progress in stabilizing its operations, strengthening its balance sheet and driving continuous improvement.
According to Hider, the results reinforce management’s confidence in the company’s strategic direction as it works to establish a stronger foundation for sustainable growth and long-term value creation.
The third-quarter performance comes as Baxter continues to align its operating model and financial reporting structure with its business priorities. The company is focusing on improving operational execution while supporting demand for products and technologies used by hospitals and other healthcare providers.
Worldwide Sales Increase 5% in the Third Quarter
Baxter reported worldwide sales of approximately $2.98 billion for the third quarter of 2026, representing a 5% increase compared with the corresponding period of the previous year on both a reported and organic basis.
The company’s sales performance reflected growth in both domestic and international markets. U.S. sales reached approximately $1.6 billion, increasing 3% on a reported basis and 5% on an organic basis. International sales totaled approximately $1.4 billion, representing a 7% reported increase and a 6% organic increase.
These results demonstrate that Baxter recorded sales growth across its geographic markets during the quarter. The difference between reported and organic growth reflects the distinct ways in which the company measures its financial performance. Reported growth reflects sales as presented in its financial statements, while organic growth adjusts for certain factors, such as foreign currency movements and other specified effects, depending on the company’s reporting methodology.
The increase in U.S. sales was supported by performance in several product categories, particularly within the Medical Products & Therapies segment. Demand for infusion systems, drug compounding services and intravenous solutions contributed to the segment’s results, although lower sales in injectables partially offset the growth.
International markets also contributed to the company’s overall performance. Sales in these markets increased on both reported and organic bases, reflecting growth across Baxter’s global operations.
The company serves healthcare providers through products and technologies designed to support a range of clinical activities, including medication delivery, infusion therapy, surgical procedures and patient monitoring and support. Demand for these offerings is influenced by hospital utilization, healthcare spending, product availability and the operational needs of medical facilities.
Baxter’s third-quarter results indicate that its business segments continued to generate growth while the company pursued efforts to strengthen its financial position and improve operational performance.
Net Income and Adjusted Earnings Reflect Different Financial Measures
On a U.S. generally accepted accounting principles (GAAP) basis, Baxter reported net income of $298 million for the third quarter of 2026, equivalent to $0.57 per diluted share.
On an adjusted basis, the company reported earnings of $0.58 per diluted share, representing a 16% decrease compared with the prior-year period. Baxter attributed the decline in adjusted earnings per share primarily to a higher effective tax rate year over year.
GAAP earnings reflect the accounting standards used in the company’s financial statements. Adjusted earnings, meanwhile, are a non-GAAP measure that excludes certain items as defined by the company. Investors often examine both measures to understand reported financial performance and management’s view of underlying business results.
The difference between the two measures means they should be considered separately rather than treated as interchangeable indicators of performance.
Baxter’s reported net income and adjusted earnings per share provide different perspectives on the company’s quarterly results. While worldwide sales increased 5%, adjusted earnings per share declined because of the factors identified by the company, including the higher effective tax rate.
The results illustrate the importance of examining revenue, profitability and cash flow together when evaluating a medical technology company’s financial performance.
Sales growth provides information about demand for products and services, while earnings measures reflect the financial impact of revenue, operating expenses, taxes and other items. Free cash flow offers a further perspective by indicating the cash generated after capital expenditures, according to the company’s reporting methodology.
Baxter continues to focus on improving its business performance while working to build a more stable financial foundation.
Free Cash Flow Reaches $448 Million
Cash generation remained an important component of Baxter’s third-quarter financial performance.
The company reported free cash flow of $448 million for the third quarter of 2026. Its year-to-date free cash flow totaled $705 million.
Free cash flow is an important financial measure because it provides insight into the cash available to a company after accounting for capital expenditures under its stated calculation. Businesses may use available cash to support debt repayment, fund investments, meet financial obligations and strengthen their balance sheets.
For a medical technology company operating across multiple product categories and geographic markets, cash generation can support a range of financial and operational priorities.
Baxter has identified balance sheet improvement and debt reduction as key areas of focus. Its third-quarter cash generation occurred alongside a debt tender offer intended to accelerate its deleveraging efforts.
The company’s focus on free cash flow is part of a wider effort to improve financial flexibility while continuing to support its operations and product portfolio.
Cash flow performance should be considered alongside earnings and revenue, as the measures reflect different aspects of the business. A company can record higher sales while facing changes in expenses, working capital requirements, taxes or investment needs that affect the amount of cash generated during a reporting period.
Baxter’s reported free cash flow provides investors with additional information about the company’s ability to generate cash while implementing its financial priorities.
Baxter Retires $864 Million in Debt Through Tender Offer
During the third quarter, Baxter completed a $600 million cash tender offer that resulted in the retirement of $864 million in debt, according to the company’s announcement.
The transaction was part of Baxter’s broader effort to accelerate deleveraging and support its investment-grade credit objectives.
Debt management remains an important consideration for companies seeking to strengthen their financial position. Reducing outstanding debt can help improve financial flexibility over time, although the overall impact depends on factors such as the company’s remaining debt obligations, interest costs, available cash and future operating performance.
Baxter’s tender offer forms part of management’s stated strategy to stabilize the business and strengthen the balance sheet. The company is pursuing this work alongside operational improvement initiatives and efforts to support sales growth across its businesses.
The ability to generate cash is relevant to these priorities because it can provide resources for managing financial obligations. However, debt reduction must also be balanced against the need to maintain investment in products, technologies, manufacturing capabilities and other business activities.
By completing the tender offer during the quarter, Baxter took a further step in its stated deleveraging efforts.
The company said its financial results reinforce its confidence in the direction of the business as it works toward sustainable growth and long-term value creation.
Medical Products & Therapies Segment Records 6% Growth
Baxter’s Medical Products & Therapies segment generated approximately $2.1 billion in sales during the third quarter of 2026, representing a 6% increase on both a reported and organic basis.
The segment’s performance was supported primarily by strength within the Infusion Therapies & Platforms division. Growth in infusion systems, drug compounding and intravenous solutions contributed to the results, while continued strong global demand for Advanced Surgery products also supported performance.
These product categories play important roles in healthcare delivery. Infusion systems are used to administer fluids and medications to patients, while intravenous solutions support a variety of clinical treatment requirements. Drug compounding services and products also contribute to medication preparation and delivery in healthcare settings.
Hospitals and other medical facilities rely on these products to support routine treatments, inpatient care and other clinical procedures. Product demand can be affected by patient volumes, hospital purchasing patterns, treatment requirements and supply availability.
Baxter’s growth in infusion therapies and platforms highlights the contribution of these product categories to the segment’s quarterly performance.
However, the results were not uniform across every product area. The company reported that reduced sales within Injectables partially offset the strength seen in other parts of the segment.
This variation demonstrates the importance of examining individual product categories alongside overall segment growth. While the segment increased sales by 6%, the performance of specific businesses differed.
Advanced Surgery products also contributed to the segment’s results, with the company reporting continued strong global demand. These products support surgical procedures and related clinical activities, making them part of the broader range of medical products supplied by Baxter.
Overall, the Medical Products & Therapies segment remained a significant contributor to Baxter’s worldwide sales during the third quarter.
Healthcare Systems & Technologies Segment Posts 4% Growth
Baxter’s Healthcare Systems & Technologies segment reported approximately $806 million in third-quarter sales, increasing 4% on both a reported and organic basis.
The segment’s performance reflected strong demand for Care & Connectivity Solutions products, supported by growth in Global Surgical Solutions and Patient Support Systems. Baxter also reported growth in Front Line Care.
These businesses provide technologies and equipment used by healthcare professionals in clinical environments. Hospitals depend on a combination of equipment, patient support technologies and connected systems to manage treatment activities and support care delivery.
Global Surgical Solutions contributes products and technologies designed for surgical settings, while Patient Support Systems serves needs associated with supporting patients during hospital care. Front Line Care includes products used by healthcare professionals in patient assessment and clinical care.
Demand across these categories can be influenced by hospital investment plans, equipment replacement cycles, clinical requirements and the need to maintain or modernize healthcare infrastructure.
The 4% increase in segment sales indicates continued growth across Baxter’s Healthcare Systems & Technologies business. Together with the performance of Medical Products & Therapies, the results show that both of the company’s reported segments contributed to overall sales growth in the third quarter.
Baxter’s reporting structure for these segments reflects changes to the company’s operating model that took effect in the second quarter of 2026.
Updated Reporting Structure Aligns With Operating Model
Beginning in the second quarter of 2026, Baxter updated its segment reporting structure to align with changes to its operating model.
The company recast previously reported segment results to conform to the updated structure. The revised presentation is intended to reflect the way Baxter organizes and manages its business operations.
Changes in segment reporting can affect how investors compare current results with prior periods. Recasting historical figures helps provide a more consistent basis for evaluating performance under the revised structure.
Baxter has made information about the updated reporting structure and historical segment results available through its investor relations resources.
For investors and analysts, understanding these reporting changes is important when assessing segment-level growth. Comparing results under consistent reporting categories can provide a clearer view of the performance of individual businesses and their contributions to the company’s overall financial position.
The updated structure also provides context for Baxter’s discussion of growth across its two reported segments during the third quarter.
Management Focuses on Stabilization and Sustainable Growth
Baxter’s third-quarter results reflect a combination of sales growth, cash generation and continued financial restructuring efforts.
Hider emphasized that the company is making progress in stabilizing its business, strengthening its balance sheet and driving continuous improvement. He said the latest performance supports management’s confidence as Baxter works to establish a stronger foundation for sustainable growth and long-term value creation.
These priorities involve several related areas of business management. Stabilizing operations requires consistent execution across product categories and geographic markets, while balance sheet improvement involves managing debt and maintaining financial flexibility.
Continuous improvement can also involve reviewing operational processes, monitoring performance and identifying opportunities to improve efficiency and execution.
For Baxter, these efforts are taking place alongside continued demand for products used in hospitals and other healthcare settings. The company’s two reported segments cover a broad range of medical products, surgical solutions, patient support systems and clinical technologies.
Maintaining growth across these businesses while managing financial obligations remains an important element of the company’s stated direction.
The third-quarter results provide an update on Baxter’s progress, including 5% worldwide sales growth, $448 million in quarterly free cash flow and the retirement of $864 million in debt through the completed tender offer.
Baxter’s third-quarter 2026 results highlight growth across its business segments and continued attention to financial stability.
Worldwide sales reached approximately $2.98 billion, with both U.S. and international markets contributing to the increase. Medical Products & Therapies reported 6% growth, while Healthcare Systems & Technologies recorded 4% growth.
The company also reported $298 million in GAAP net income, or $0.57 per diluted share, and adjusted earnings of $0.58 per diluted share. Adjusted earnings per share declined 16% year over year, primarily reflecting a higher effective tax rate.
Free cash flow reached $448 million for the quarter and $705 million year to date, while the completion of the cash tender offer supported Baxter’s efforts to reduce debt and strengthen its balance sheet.
The company’s results demonstrate that revenue growth, earnings performance, cash generation and debt management remain distinct but interconnected elements of its financial strategy.
As Baxter continues to implement changes to its operating model and reporting structure, the performance of its medical products, infusion therapies, surgical solutions and healthcare technologies will remain central to its business.
The company says it remains focused on stabilizing operations, improving execution and creating a stronger foundation for sustainable growth. Its third-quarter performance provides a snapshot of progress toward those priorities while highlighting areas that will continue to require management attention.
With growth across both reported segments and continued efforts to strengthen its financial position, Baxter is seeking to balance near-term operational performance with its longer-term objectives for stability and value creation.
Source link: https://www.baxter.com/
